Advaxis (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Advaxis (NASDAQ:ADXSGet Rating) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

NASDAQ:ADXS opened at $0.08 on Tuesday. Advaxis has a one year low of $0.07 and a one year high of $0.76.

About Advaxis (Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Read More

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.